Invitae Comprehensive Lipidemia Panel
Use
This test provides a comprehensive analysis of genes associated with a variety of inherited lipidemias. Lipidemias are characterized by abnormal levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and/or triglycerides. These abnormalities increase the risk for cardiovascular events and can cause additional clinical complications. Early and appropriate medical intervention can reduce the risk of cardiovascular events. At-risk relatives could be identified and preventive therapy could be initiated. Comprehensive testing allows for efficient evaluation of multiple disorders based on a single indication.
Special Instructions
Variants in CETP and LIPG are reported as 'benign, reportable variants' which may explain elevated HDL levels but do not cause symptoms or a known risk for cardiovascular disease. These cannot be ordered for family variant testing, only included if full gene testing is requested.
Limitations
The assay achieves >99% analytical sensitivity and specificity for single nucleotide variants, insertions, and deletions <15bp and exon-level duplications. Some larger insertions/deletions and structural rearrangements may not be detected, and certain non-coding regions are not covered. Sequence changes in promoter and certain non-coding regions are not covered.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)